atorvastatin has been researched along with Experimental Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, H; Li, Z; Zheng, N; Zhi, Y | 1 |
| Ai, A; Ai, J; Ebrahimi-Barough, S; Farahani, MS; Goodarzi, A; Khanmohammadi, M; Khodayari, H; Khodayari, S; Mohandesnezhad, S | 1 |
| Li, J; Long, C; Peng, P; Wei, W | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Ajith, TA; Anu, V; Riji, T | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Belisario, DC; Bolli, E; Bosia, A; Calogero, RA; Cavallo, F; Pinto, H; Riganti, C | 1 |
7 other study(ies) available for atorvastatin and Experimental Neoplasms
| Article | Year |
|---|---|
Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Cell Line; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Female; Flavones; Humans; Kinetics; Ligands; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Oligopeptides; Particle Size | 2020 |
Simultaneous impact of atorvastatin and mesenchymal stem cells for glioblastoma multiform suppression in rat glioblastoma multiform model.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Glioblastoma; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Neoplasms, Experimental; Rats; Rats, Wistar | 2020 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Glioblastoma; Humans; Mice; Neoplasms, Experimental; ras Proteins; Signal Transduction; Temozolomide; Tumor Cells, Cultured | 2017 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Mice; Models, Chemical; Neoplasms, Experimental; Pyrroles; Reactive Oxygen Species | 2008 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Hypolipidemic Agents; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 6; Neoplasms, Experimental; NF-kappa B; Pyrroles; ras Proteins; Receptor, ErbB-2; rhoA GTP-Binding Protein; Terpenes | 2011 |